Delirium is the most common manifestation of brain dysfunction in critically ill patients. 5 key findings →
Participants: 25,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Hospice enrollment correlates with reduced Medicare expenditures among younger decedents with cancer but increased expenditures among decedents without cancer and those older than 84 years of age. 2 key findings →
Design: retrospective cohort Participants: 245 Evidence: moderate
Full summary, score breakdown and related studies → Original source
There is need for clearer articulation of the likely mechanisms by which advance care planning can lead to reduced care costs or improved cost-effectiveness, particularly for people who retain capacity. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Telemental health (TMH) for older patients has the potential to increase access to geriatric specialists, reduce travel times for patients and providers, and reduce ever growing healthcare costs. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Direct measurement of prevalence of palliative care needs on a population basis is feasible. 1 key finding →
Design: cross-sectional Participants: 785 Evidence: low
Full summary, score breakdown and related studies → Original source
Description The American College of Physicians developed this guidance statement to guide clinicians in selecting targets for pharmacologic treatment of type 2 diabetes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Immobility-related complications are very common in the first year after a severely disabling stroke. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Further investments to facilitate dying at home are desirable. 2 key findings →
Participants: 135,000 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We examined state variations in assisted living (AL) regulatory policies for admission/retention, staffing/training, medication management, and dementia care. 3 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The benefits of expanding funding for Medicaid long-term care home and community-based services (HCBS) relative to institutional care are often taken as self-evident. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer's disease (AD), linked to faster disease progression and earlier admission to nursing homes. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
The increasing elderly population is driving higher utilization rates of long-term care facilities, where residents often have multiple chronic diseases, making them potential candidates for palliative care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These findings indicate that the early diagnosis and treatment of AD are not only socially desirable in terms of increasing economic efficiency, but also fiscally attractive from both state and federal perspectives. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increasing costs of institutional care for the aged have occasioned a variety of government cost containment measures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study examines total formal and informal care costs attributable to Alzheimer's disease for persons living in the community and in institutions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
An analysis of interaction terms in the Cox regression model found that those individuals who utilized in-home help services earlier in their dementia caregiving careers were more likely to delay institutionalization. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hospitalizations and emergency department (ED) visits for people with Alzheimer's disease and related disorders are of particular concern because many of these patients are physically and mentally frail, and the care delivered in these settings is costly. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Medicare Help at Home—a proposal to add supplemental home- and community-based services—could be financed by income-related cost-sharing, beneficiary monthly premiums of $42, and an incremental payroll tax on employers and employees of 0.4 percent. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the context of an aging population, China’s elderly care market is experiencing a period of significant transformation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over the past decade, the CMS has introduced numerous value-based policy initiatives. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The wave of ‘silver tsunami’ sweeping over the developed world means that the number of dementia patients expected to double to 75.6 million by 2030. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In fact, average benefits are considered modest compared with the benefits of other developed countries. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events